Fenofibrates and the Prevention of Cardiovascular Risk

From: http://www.touchendocrinology.com/articles/fenofibrates-and-prevention-cardiovascular-risk?page=0%2C2

Davidson Michael H

US Endocrine Disease 2006 Issue 2
Published: October 2008
download article

Additional research is needed to corroborate our findings with other TG-lowering agents or combinations of agents. Data from clinical outcomes trials will also be needed to demonstrate that treatmentinduced changes in LDL particle size will translate into reductions in event risk above those attributable to modification of the standard lipoprotein profile.

In conclusion, our investigations indicate that fenofibrate lowers TG concentration and produces other favorable changes in several lipid markers for cardiovascular disease risk in hypertriglyceridemic subjects with metabolic syndrome. Increases in LDL particle size were minor or non-existent unless the ontreatment TG concentration was low enough to produce a shift in LDL subclass distribution pattern.

This threshold TG value was <200mg/dl>